[Determination of ER-D5 (estrogen receptor related antigen) in prostatic cancer and its significance].
The existence of an estrogen receptor and various other sex steroid receptors has been confirmed in prostatic cancer. However, the action mechanism of hormone therapy and relationship between the disappearance of hormone response, which is observed in the recurrence of prostatic cancer, and various sex steroid receptors have yet to be identified. The use of monoclonal antibody ERICA is known as a method of detecting the estrogen receptor in the immuno-histological chemistry method. However, this monoclonal antibody is difficult to use on paraffin sections. Therefore, using monoclonal antibody D5, which allows ER-D5 detection of the estrogen receptor related antigen on paraffin sections, we investigated whether or not estrogen receptors are present in the prostatic cancer preparation and studied the survival rate of prostatic cancer as well as relationship with recurrence. Positive ER-D5 results were obtained in 37 of 93 prostatic cancer cases (39.8%) and in all 20 prostatic hypertrophy cases (100%). ER-D5 tended to be more densely stained in prostatic hypertrophy than in prostatic cancer. The survival rate was obviously higher in the ER-D5 positive prostatic cancer cases than in ER-D5 negative cases for a certain period of time after the start of treatment. Despite differences in the histo-differentiation degree and clinical stage of prostatic cancer, the ER-D5 positive percentage did not change and remained between 35% and 45%. In cases where another prostatic cancer preparation was taken because of recurrence of prostatic cancer, there were no ER-D5 positive cases at the time of recurrence.(ABSTRACT TRUNCATED AT 250 WORDS)
Ohishi
M
M
Department of Urology, Nagoya University School of Medicine.
Miyake
K
K
Koshikawa
T
T
Asai
J
J
Murase
T
T
D000230:Adenocarcinoma / Q000276:immunology* / Q000401:mortality / Q000628:therapy; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000032:analysis*; D003131:Combined Modality Therapy; D006360:Heat-Shock Proteins; D006801:Humans; D008297:Male; D008875:Middle Aged; D010750:Phosphoproteins / Q000032:analysis*; D011470:Prostatic Hyperplasia / Q000276:immunology; D011471:Prostatic Neoplasms / Q000276:immunology* / Q000401:mortality / Q000628:therapy; D011960:Receptors, Estrogen; D015996:Survival Rate
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D006360:Heat-Shock Proteins; D010750:Phosphoproteins; D011960:Receptors, Estrogen